Answers are grounded in this paper and cite their sources.
Background and Objectives: Coexisting methemoglobinemia and hemolytic anemia is a rare, life-threatening scenario driven by oxidative stress. In this study, hemolysis was predominantly drug- or toxin-induced in patients with either normal or deficient glucose-6-phosphate dehydrogenase ( G6PD activity, occurring when overwhelming oxidative stress exceeded intrinsic cellular antioxidant defenses. Management in G6PD deficiency is challenging, as methylene blue can exacerbate acute hemolysis. This study is designed as an exploratory investigation that seeks to evaluate clinical management approaches and identify potential factors affecting survival among the analyzed cases. Materials and Methods: This systematic review and pooled analysis evaluated adult cases from PubMed and Embase (inception to September 2026). Results: Seventy cases (median age: 50 years; 57% G6PD-deficient) were analyzed, with oxidant exposures driving 82% of cases, combining medication exposures (49%, n = 34) and toxic substance exposures (33%, n = 23). The median methemoglobin level was 10.0% (range: 1.0–46.0%). The median day for hospitalization was 8 days (range: 0–30). Treatments included supportive care (n = 24), ascorbic acid alone (n = 18), extracorporeal therapies (n = 15), combination therapy (n = 14), and methylene blue alone (n = 10). Overall mortality was 14%. In multivariable modeling, exploratory associations were observed between mortality and clinical factors such as advanced age and highest methemoglobin levels. Conclusions: Methylene blue administration was not clinically safe in G6PD deficiency. Advanced age and peak methemoglobin levels serve as tentative mortality predictors. These exploratory findings underscore the need for vigilant, individualized management.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: